HOME >> MEDICINE >> NEWS
Survival benefit for rheumatoid arthritis patients treated with methotrexate

The anticancer drug methotrexate could have a substantial survival benefit among patients with rheumatoid arthritis, conclude authors of a prospective US study in this weeks issue of THE LANCET.

Rheumatoid arthritis is a chronic inflammatory disease which results in reduced life-expectancy and is associated with cardiovascular disease, infection, and cancer. Low-dose methotrexate is the main choice of antirheumatic therapy for rheumatoid arthritis, although its effect on mortality for patients with the disease is not known.

Hyon Choi from Harvard Medical School and Harvard School of Public Health, Frederick Wolfe from University of Kansas School of Medicine, USA, and colleagues prospectively studied 1240 patients with rheumatoid arthritis over the past two decades. 191 individuals died during follow-up. Patients who began treatment with methotrexate (around half of the study population) had more severe rheumatoid arthritis. After adjustment for this confounding factor, methotrexate was found to have a 60% survival benefit for all-cause mortality compared with those who did not use methotrexate, and a 70% survival benefit for cardiovascular death.

Hyon Choi comments: Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This gain in life expectancy could be considered in selecting a cost-effective, disease-modifying antirheumatic drug on a long-term basis. Additionally, the survival benefit of methotrexate would set a standard against which new disease-modifying antirheumatic drugs should be compared.


'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7424-4949
Lancet
4-Apr-2002


Page: 1

Related medicine news :

1. Survival sex and substance abuse may hinder HIV prevention efforts
2. Survival improves in clinical trial for severe birth defect, with or without fetal surgery
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. American Heart Association Comment: Contributions Of Trends In Survival And Coronary-Event Rates To Changes In Coronary Heart Disease Mortality
5. Early Heart Repair For Marfan Syndrome Patients Critical To Survival
6. Intensive Care Before A Major Op May Improve Survival
7. Sex And Survival: In Some Matters Of The Heart Women Have The Edge
8. Study: Birth Defects Decrease Survival, Childbirth, Boost Risk Of Similar Defects
9. Study Indicates That Medicare Costs Are Higher -- And Survival Rate Is Better --At Major Teaching Hospitals Survive Climate Change
10. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
11. Beta Blocker Significantly Improves Heart Failure Survival

Post Your Comments:
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
Cached News: